Targeting MET Resistance: Savolitinib Plus Osimertinib Extends Survival Over Chemotherapy in Phase 3 SAFFRON Trial

When EGFR-mutated lung cancer stops responding to Tagrisso, the MET pathway is often to blame. A phase 3 trial found that adding the MET inhibitor savolitinib to Tagrisso helped patients live longer than chemotherapy did, but serious side effects were more common.